IPS HEART — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

IPS HEART is a private, pre-clinical stage biotech founded in 2015 and based in San Diego, California. The company is pioneering iPSC-derived cellular therapies designed to regenerate functional muscle tissue for cardiac and skeletal muscle disorders, moving beyond symptomatic treatment to potential cures. It has garnered regulatory recognition from the FDA, including Orphan Drug and Rare Pediatric Disease Designations. The company is currently pre-revenue and is advancing a pipeline focused on two lead programs for heart failure and DMD.

CardiologyNeuromuscular Diseases

Technology Platform

Proprietary platform using induced pluripotent stem cells (iPSCs) to generate an unlimited supply of cardiomyocytes and myocytes for allogeneic, off-the-shelf therapies aimed at regenerating heart and skeletal muscle.

Opportunities

The company addresses massive unmet needs in heart failure and DMD with a potentially curative, single-course treatment.

FDA Orphan and Rare Pediatric Disease Designations provide accelerated pathways, fee waivers, and extended market exclusivity, enhancing commercial potential.

Success could open avenues for platform application in other degenerative muscle and tissue disorders.

Risk Factors

High scientific risk associated with engraftment, functional integration, and long-term safety of iPSC-derived cells.

Regulatory path for novel allogeneic cell therapies is complex and uncertain.

Intense competition from other modalities (gene therapy, small molecules) in both target indications.

Competitive Landscape

In heart failure, competitors include large pharma with standard care drugs, device companies, and other cell therapy firms using different cell types (e.g., mesenchymal stem cells). In DMD, competition is fierce from gene therapy companies (e.g., Sarepta, Pfizer) and exon-skipping therapies, though IPS HEART's muscle regeneration approach is distinct from gene replacement or restoration strategies.

More companies in Cell & Gene Therapy →More companies in United States →